"52792 Lebrikizumab provides stable skin response with no or minimal fl" by Jonathan Sliverberg, Andreas Wollenberg et al.
 

52792 Lebrikizumab provides stable skin response with no or minimal fluctuations for up to two years in patients with atopic dermatitis

Document Type

Conference Proceeding

Publication Date

9-1-2024

Publication Title

J Am Acad Dermatol

Abstract

Lebrikizumab, a high-affinity IL-13 inhibitor, demonstrated safety and efficacy as monotherapy through 52 weeks of treatment in adults and adolescents (≥40 kg) with moderate-to-severe atopic dermatitis (AD) in recent phase 3 trials (ADvocate1, NCT04146363; ADvocate2, NCT04178967). Here, we assessed the stability of response after 2 years of lebrikizumab in the subpopulation of patients who responded at week 16 to 250 mg lebrikizumab every two weeks (LEB Q2W) without the use of rescue medication and who then received LEB Q2W or LEB every four weeks (LEB Q4W) in ADvocate1 and 2 and continued the same treatment (LEB Q2W, n=82; LEB Q4W, n=99) in ADjoin (NCT04392154), a long-term extension study of lebrikizumab. Response at week 16 was defined as an Investigators Global Assessment 0/1 or a ≥75% reduction in Eczema Area and Severity Index (EASI-75). Stability of response with treatment from week 16 through week 104 (ADjoin week 52) was defined as the proportion of patients with an EASI-75 response during ≥80% of attended visits, using all observed data. A ≥90% reduction in EASI (EASI-90) was also assessed. A stable EASI-75 response was achieved for 96.0% of patients receiving LEB Q4W and 91.5% for LEB Q2W. A stable EASI-90 response was achieved for 64.6% of patients receiving LEB Q4W and 59.8% for LEB Q2W. In summary, most lebrikizumab responders had a stable EASI-75 response with no or minimal fluctuations during 2 years of treatment.

Volume

91

Issue

3

First Page

AB59

Find It @ Sladen

Share

COinS